新颖的抗癌策略通过提高癌细胞的致死能力来减少对健康组织的副作用。开发具有良好生物利用度和选择性的有效颗粒仍然存在问题。对于不良特征，可以使用绿色化学来合成最好的化合物，或者对天然颗粒进行改进。以酞菁 (Pcs) 为模型的光动力疗法 (PDT) 仍然提供第二代敏化剂，并辅以金属离子，如 Zn2、Al3 或 Ga3。氢氧化镓八羧基酞菁 (Ga(OH)PcOC) 专为皮肤癌治疗而设计，用作正常皮肤细胞系、成纤维细胞 (NHDF) 和角质形成细胞 (HaCaT) 的促凋亡和促氧化剂，具有良好的前景体外对黑色素瘤癌细胞（Me45）的选择性。与之前报道的结果相比，ZnPcOC 以较高剂量作用于皮肤细胞系，对 Ga(OH)PcOC 的敏感性可以有效减少敏化剂剂量。使用 24 小时 MTT 活力以及细胞计数促氧化和促凋亡测定法进行测试，新型 Ga(OH)PcOC 颗粒的有效剂量在 Me45 癌细胞上从 30 µM 显着降低至 6 µM。这种有前景的光敏剂不会降低正常成纤维细胞和角质形成细胞的活力，且不会导致活性氧（ROS）升高或诱导细胞凋亡。对先前发现的改进是基于 Ga 的光敏剂对癌症 Me45 细胞具有更好的选择性，然后在基于 Zn 的化​​合物中观察到。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。

Novel anticancer strategies reduce side effects on healthy tissues by elevating the lethal abilities of cancer cells. The development of effective particles with good bioavailability and selectivity remains problematic. For undesirable features, green chemistry is used to synthesize the best compounds, or natural-based particles are improved. Photodynamic therapy (PDT), modelled on phthalocyanines (Pcs), still delivers second-generation sensitizers which are complemented with metal ions, such as Zn2+, Al3+, or Ga3+. Gallium octacarboxyphthalocyanine hydroxide (Ga(OH)PcOC), was designed for skin cancer treatment, and was used as a pro-apoptotic and pro-oxidative agent on normal skin cell lines, fibroblasts (NHDF), and keratinocytes (HaCaT), with promising selectivity against melanoma cancer cells (Me45) in vitro. Compared to the previous reported findings, where the ZnPcOC acted on the skin cell lines at higher doses, the sensitivities to the Ga(OH)PcOC allows for an effective reduction of the sensitizer dose. The effective dose, for a novel Ga(OH)PcOC particle, was significantly reduced from 30 µM to 6 µM on Me45 cancer cells, tested using 24 h MTT viability, as well as cytometric pro-oxidative and pro-apoptotic assays. The promising photosensitizer did not reduce viability in normal fibroblasts and keratinocytes without reactive oxygen species (ROS) elevation or apoptosis induction. The improvement to the previous findings is better Ga-based photosensitizer selectivity against the cancer Me45 cells, then observed in Zn-based compounds.Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.